

Supplementary material

Tymińska A, Ozierański K, Balsam P, et al. The prevalence and association of major ECG abnormalities with clinical characteristics and the outcomes of real-life heart failure patients — Heart Failure Registries of the ESC. Kardiol Pol. 2021.

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. Univariable analysis of predictors of the primary and secondary endpoints in heart failure patients at one-year

Variable	Primary endpoint			Secondary endpoint		
	HR	95% CI	P-value	HR	95% CI	P-value
Abnormal ECG	1.73	1.11–1.73	0.02	1.52	1.15–2.01	0.004
QTc interval ≥ 450	1.78	1.35–2.33	<0.001	1.63	1.36–1.96	<0.001
LVH	0.78	0.54–1.12	0.18	0.87	0.69–1.11	0.27
Pathological Q-wave	1.08	0.81–1.45	0.61	1.07	0.87–1.30	0.54
QRS duration ≥ 120	2.06	1.57–2.71	<0.001	1.648	1.36–1.99	<0.001
LBBB	0.92	0.60–1.40	0.69	1.09	0.83–1.42	0.55
Tachycardia (>100 b.p.m.)	2.78	1.87–4.13	<0.001	1.65	1.19–2.28	0.002
Abnormal rhythm	1.50	1.14–1.97	0.003	1.30	1.08–1.57	0.01
Male	0.79	0.59–1.03	0.08	0.80	0.7–0.97	0.03
LVEF	0.986	0.976–0.996	0.01	0.980	0.973–0.987	<0.001
Age	1.05	1.03–1.06	<0.001	1.02	1.01–1.02	<0.001
BMI	0.96	0.94–0.99	0.01	0.99	9.97–1.004	0.14

SBP	.992	0.986–0.997	0.004	.991	0.987–0.994	<0.001
AF history	1.47	1.13–1.93	0.01	1.27	1.06–1.53	0.01
NYHA (class III or IV vs I or II)	2.24	1.34–3.73	<0.001	2.85	2.22–3.65	<0.001
Serum sodium	0.91	0.89–0.93	<0.001	0.94	0.92–0.96	<0.001
HGB	0.85	0.80–0.91	<0.001	0.88	0.84–0.92	<0.001
Pacemaker	1.50	0.95–2.38	0.09	1.16	0.82–1.64	0.40
CRT	1.82	1.11–2.98	0.02	1.53	1.06–2.20	0.02
ICD	0.99	0.69–1.41	0.95	1.21	0.96–1.52	0.10
Smoking	1.06	0.80–1.40	0.66	1.12	0.92–1.35	0.26
Diabetes	1.50	1.14–1.98	0.004	1.47	1.22–1.78	<0.001
Stroke	.88	0.57–1.37	0.57	1.14	0.87–1.50	0.36
COPD	1.89	1.40–2.55	<0.001	1.52	1.23–1.89	<0.001
CKD	2.27	1.70–3.04	<0.001	1.93	1.57–2.37	<0.001
ACE-I	0.51	0.38–0.67	<0.001	0.62	0.51–0.75	<0.001
ARB	0.50	0.28–0.87	0.02	0.79	0.58–1.07	0.12
B-blocker	0.29	0.218–0.40	<0.001	0.557	0.435–0.714	<0.001
Diuretics	0.79	0.57–1.10	0.17	1.28	0.98–1.66	0.07
Digitalis	1.30	0.96–1.75	0.09	1.40	1.15–1.71	0.001
Statins	0.66	0.51–0.87	0.003	0.92	0.76–1.11	0.39
Antiplatelets	0.83	0.63–1.07	0.17	1.01	0.84–1.22	0.91
Anticoagulants	0.85	0.64–1.12	0.24	1.11	0.92–1.33	0.28
Amiodarone	1.54	1.025–2.30	0.04	1.39	1.04–1.85	0.02
Antiarrhythmics	0.89	0.49–1.64	0.71	0.84	0.54–1.31	0.44
HF type						
HFmrEF (reference)	1.00	1.00–1.00	1.00	1.00	1.00–1.00	1.00
HFrEF	1.915	1.22–3.02	0.01	1.58	1.19–2.09	0.001

HFpEF	1.67	1.01–2.77	0.045	1.11	0.80–1.53	0.53
-------	------	-----------	-------	------	-----------	------

Abbreviations: ACE-I, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; ECG, electrocardiogram; HF, heart failure; HFmrEF – heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HGB, hemoglobin; HR, hazard ratio; ICD, implantable cardioverter-defibrillator; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; LVH, left ventricle hypertrophy, NYHA, New York Heart Association Class; SBP, systolic blood pressure